Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Retained Earnings (2016 - 2025)

Coherus Oncology's Retained Earnings history spans 13 years, with the latest figure at -$1.4 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 502797.82% year-over-year to -$1.4 billion; the TTM value through Dec 2025 reached -$1.4 billion, down 502797.82%, while the annual FY2025 figure was -$1.4 billion, 502797.82% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.4 billion at Coherus Oncology, down from -$203000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at -$203000.0 in Q3 2025 and bottomed at -$1.6 billion in Q4 2023.
  • The 5-year median for Retained Earnings is -$275000.0 (2024), against an average of -$425.8 million.
  • The largest annual shift saw Retained Earnings crashed 634237.35% in 2023 before it soared 99.98% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$270000.0 in 2021, then rose by 7.78% to -$249000.0 in 2022, then plummeted by 634237.35% to -$1.6 billion in 2023, then skyrocketed by 99.98% to -$275000.0 in 2024, then tumbled by 502797.82% to -$1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Retained Earnings are -$1.4 billion (Q4 2025), -$203000.0 (Q3 2025), and -$275000.0 (Q2 2025).